Review Article: The role of Neo adjuvant Chemotherapy in the treatment of Breast Cancer

Kamal Eldein Hamed Mohamed, Muna Mohamed Ahmed Kaboush, Abdelsamie Abdalla Mohamed

Abstract


Neoadjuvant chemotherapy (NACT) in breast cancer is giving chemotherapy before surgery, it’s an effective
initial treatment for large tumors, locally advanced cancer and inflammatory breast cancer. It downstage
the disease, allow lesser extensive surgery e.g. breast conservative surgery, the benefit is greater for those
who attain pathological complete response (PCR), who get a significantly better overall survival (OS), and
progression free survival (PFS), compared with those who don’t. This approach is very important in Sudan
where the majority, almost 65 % of patients present with locally advanced disease, most of them are denied
this treatment.

Keywords


The role ;Neo adjuvant ;Chemotherapy ; treatment ;Breast Cancer

Full Text:

PDF

References


Thompson AM, Moulder SL. Neoadjuvant

chemotherapy in breast cancer. Ann Onco.

; 23: 231-236.

Koplin LM, O’Connell TX. A new approach

to the management of primary unresectable

carcinoma of the breast: Is radiation therapy

necessary? Am J Clin Oncol 1983; 6: 599-604.

Jaiyesimi IA, Buzdar AU, Hortobagyi G.

Inflammatory breast cancer: a review. J Clin

Oncol. 1992; 10: 1014-1024.

Liu SV, Melstrom L, Yao K, et al. Neoadjuvant

therapy for breast cancer. Surg Oncol. 2010;

:283-91.

Mieog JSD, van der Hage JA, van de Velde CJ.

Neoadjuvant chemotherapy for operable breast

cancer. Br J Surg. 2007; 94:1189-1200.

Carey LA, Dees EC, Sawyer L, et al. The

triple negative paradox: primary tumor

chemosensitivity of breast cancer subtypes.

Clin Cancer Res. 2007; 15:2329-34.

von Minckwitz G, Martin M. Neoadjuvant

treatments for triple-negative breast cancer

(TNBC). Ann Oncol. 2012; 23:35-9.

Oakman C, Viale G, Di Leo A. Management

of triple negative breast cancer. Breast. 2010;

:312-21.

Kuehn T, Bauerfeind I, Fehm T, et al. Sentinellymph-

node biopsy in patients with breast cancer

before and after neoadjuvant chemotherapy

(SENTINA): a prospective, multicentre cohort

study. Lancet Oncol. 2013; 14:609-18.

Haazem Ai, Eiman S, Mohamed A, et al.

Controversies in SLNB in breast cancer.

Bimomedical Research intern J. 2015, 2015, ID

http//dx.doi.org/10.

Tan VK, Goh BK, Fook-Chong S, The

feasibility and accuracy of sentinel lymph node

biopsy in clinically node-negative patients after

neoadjuvant chemotherapy for breast cancer-a

systematic review and meta-analysis. J Surg

Oncol. 2011; 104:97-103.

Davidson NE, Morrow M. Sometimes a great

notion-an assessment of neoadjuvant systemic

therapy for breast cancer. J Natl Cancer Inst.

; 97:159-61.

Symmans WF, Peintinger F, Hatzis C.

Measurement of residual breast cancer

burden to predict survival after neoadjuvant

chemotherapy. J Clin Oncol. 2007; 25:4414-22.

David M, Nicholas P, John P. Assessment of

Neoadjuvant chemotherapy in breast cancer. J.

National Ca inst. 2005: 976:188-194.

The role of Neo adjuvant Chemotherapy in the treatment of Breast Cancer

Wolmark N, Wang J, Mamounas E, et al.

Preoperative chemotherapy in patients with

operable breast cancer: nine-year results from

National Surgical Adjuvant Breast and Bowel

Project B-18. J Natl Cancer Inst Monogr.

;(30):96-102.

Esserman LJ, Berry DA, DeMichele A, et

al. Pathologic complete response predicts

recurrence-free survival more effectively by

cancer subset: results from the I-SPY 1 TRIAL-

-CALGB 150007/150012, ACRIN 6657. J Clin

Oncol. 2012; 30:3242-9.

Esserman LJ, Pero M, Cheng, De Michele

A. Breast cancer molecular profiles and

tumor response for neoadjuvant doxurubcine

and paclitaxil; The I-SPY TRIAL (CALGB

/150012, ACRIN 6657). J. Clin. Oncol.

, 27, LBA515.

von Minckwitz G, Kümmel S, Vogel P, et al.

Intensified neoadjuvant chemotherapy in earlyresponding

breast cancer: phase III randomized

GeparTrio study. J Natl Cancer Inst. 2008; 100:

-62.

Jones S, Holmes FA, O’Shaughnessy J,

et al. Docetaxel With Cyclophosphamide

Is Associated With an Overall Survival

Benefit Compared With Doxorubicin and

Cyclophosphamide: 7-Year Follow-Up of US

Oncology Research Trial 9735. J Clin Oncol.

; 27:1177-83.

Wu K, Yang Q, Liu Y, et al. Meta-analysis on

the association between pathologic complete

response and triple-negative breast cancer

after neoadjuvant chemotherapy. World J Surg

Oncol. 2014; 12:95.

Moja L, Brambilla C, Compagnoni A, et al.

Trastuzumab containing regimens for early

breast cancer. April 2012, Cochrane Database

Systematic Reviews, DO1 10.

Viani GA, Afonso SL, Stefano EJ, et al.

Adjuvant trastuzumab in the treatment of her-

-positive early breast cancer: a meta-analysis

of published randomized trials. BMC Cancer.

; 7:153.

Green MC, Buzdar AU, Smith T, et al. Weekly

paclitaxel improves pathologic complete

remission in operable breast cancer when

compared with paclitaxel once every 3 weeks.

J Clin Oncol. 2005; 23:5983-92.

Bear HD, Tang G, Rastogi P, et al. Bevacizumab

added to neoadjuvant chemotherapy for breast

cancer. N Engl J Med. 2012; 366:310-20.

von Minckwitz G, Rezai M, Loibl S, et al.

Capecitabine in addition to anthracyclineand

taxane-based neoadjuvant treatment in

patients with primary breast cancer: phase

III GeparQuattro study. J Clin Oncol. 2010;

:2015-23.

Gogas H, Foutzilas G. The role of taxanes as

a component of neo adjuvant chemotheapy for

breast cancer. Ann Onco. 2013; 14:667- 674.

Cristofanilli M, Buzdar AU, Sneige N, et al.

Paclitaxel in the multimodality treatment for

inflammatory breast carcinoma. Cancer. 2001;

:1775-82.

Limentani SA, Brufsky AM, Erban JK, et al.Phase

II study of neoadjuvant docetaxel, vinorelbine,

and trastuzumab followed by surgery and

adjuvant doxorubicin plus cyclophosphamide

in women with human epidermal growth factor

receptor 2-overexpressing locally advanced

breast cancer. J Clin Oncol. 2007; 25:1232-8.

Thompson AM, Moulder-Thompson SL.

Neoadjuvant treatment of breast cancer. Ann

Oncol. 2012; 23: 231-6.

Ellis MJ, Coop A, Singh B, et al. Letrozole is

more effective neoadjuvant endocrine therapy

than tamoxifen for ErbB-1- and/or ErbB-2-

positive, estrogen receptor-positive primary

breast cancer: evidence from a phase III

randomized trial. J Clin Oncol. 2001; 19:3808-

Seo JH, Kim YH, Kim JS. Meta-analysis of preoperative

aromatase inhibitor versus tamoxifen

Kamal Eldein Hamed Mohamed, Muna Mohamed Ahmed Kaboush, Abdelsamie Abdalla Mohamed

in postmenopausal woman with hormone

receptor-positive breast cancer. Cancer

Chemother Pharmacol. 2009; 63:261-6.

Seo JH, Kim YH, Kim JS. Aromatase inhibitors

in hormone positive breast cancer. Chemo.

Pharmacology J. 2009, 63:2001-2006.

Ellis MJ, Suman VJ, Hoog J, et al. Randomized

phase II neoadjuvant comparison between

letrozole, anastrozole, and exemestane for

postmenopausal women with estrogen receptorrich

stage 2 to 3 breast cancer: clinical and

biomarker outcomes and predictive value of

the baseline PAM50-based intrinsic subtype--

ACOSOG Z1031. J Clin Oncol. 2011; 29:2342-

Semiglazov VF, Semiglazov VV, Dashyan

GA, et al. Phase 2 randomized trial of primary

endocrine therapy versus chemotherapy

in postmenopausal patients with estrogen

receptor-positive breast cancer. Cancer. 2007;

:244-54.

Kümmel S, Holtschmidt J, Loibl S. Surgical

treatment of primary breast cancer in the

neoadjuvant setting. Br J Surg. 2014; 101:912-


Refbacks

  • There are currently no refbacks.


ISSN: 1858-5345